Faculty of Veterinary Science
基本情報
- 所属
- 日本獣医生命科学大学 獣医学部 獣医学科 獣医内科学研究室 准教授
- 研究者番号
- 80610708
- J-GLOBAL ID
- 200901030800791787
- researchmap会員ID
- 6000011900
研究分野
1経歴
5-
2020年5月 - 現在
-
2020年4月 - 現在
-
2015年4月 - 2020年3月
-
2011年4月 - 2015年3月
-
2013年4月 - 2014年6月
学歴
2-
2005年4月 - 2009年3月
-
1999年4月 - 2005年3月
論文
76-
Journal of Veterinary Internal Medicine 2024年4月25日
-
Veterinary journal (London, England : 1997) 304 106090-106090 2024年2月28日 査読有り招待有り筆頭著者責任著者Inflammatory bowel disease (IBD) is a major subtype of chronic enteropathies in dogs and cats. Conventional drugs such as immunomodulatory medicines as glucocorticoids and/or other anti-inflammatory are mainly applied for treatment. However, these drugs are not always effective to maintain remission from IBD and are limited by unacceptable side effects. Hence, more effective and safe therapeutic options need to be developed. Mesenchymal stem cells (MSCs) are multipotent stem cells with a self-renewal capacity, and have immunomodulatory, anti-inflammatory, anti-fibrotic, and tissue repair properties. Therefore, the application of MSCs as an alternative therapy for IBD has great potential in veterinary medicine. The efficacy of adipose tissue-derived MSC (ADSC) therapy for IBD in dogs and cats has been reported, including numerous studies in animal models. However, treatment outcomes in clinical trials of human IBD patients have not been consistent with preclinical studies. MSC-based therapy for various diseases has received widespread attention, but various problems in such therapy remain, among which no consensus has been reached on the preparation and treatment procedures for MSCs, and cellular heterogeneity of MSCs may be an issue. This review describes the current status of ADSC therapy for canine and feline IBD and summarizes the cellular heterogeneity of canine ADSCs, to highlight the necessity for further reduction or elimination of MSCs heterogeneity and standardization of MSC-based therapies.
-
International Journal of Molecular Sciences 2023年12月14日 査読有り責任著者
-
Journal of veterinary internal medicine 2023年8月18日 査読有りBACKGROUND: Pulmonary hypertension (PH) secondary to respiratory disease is caused by pulmonary vascular remodeling and hypoxia. Severe PH can induce various clinical signs, including syncope and right-sided heart failure. HYPOTHESIS/OBJECTIVES: To investigate the echocardiographic characteristics in dogs with PH secondary to respiratory diseases. ANIMALS: Thirty-one dogs with respiratory diseases with or without PH and 15 healthy dogs. METHODS: Prospective cross-sectional study. Dogs were classified according to respiratory disease (obstructive airway/lung disease [OALD] or restrictive lung disease [RLD]) and PH-relevant signs. The association between echocardiographic variables and PH (classified by respiratory disease and PH-relevant signs) was investigated. RESULTS: Twenty-one dogs were diagnosed with PH; of these, 11 showed PH-related signs (OALD, n = 2; RLD, n = 9), 14 had right ventricular hypertrophy, and 19 had pulmonary arterial enlargement. Right ventricular dysfunction and dilatation were observed only in dogs with PH-related signs (n = 10). Left and right ventricular stroke volumes were significantly lower in dogs with PH (median [interquartile range]: 17.2 [12.4-20.8] and 16.8 [15.3-29.5] mL/m2 , respectively). Dogs with RLD had higher echocardiography-estimated pulmonary vascular resistance than those with OALD (median [interquartile range]: 3.1 [1.9-3.3] and 1.6 [1.3-2.2], respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: Pulmonary arterial enlargement was the most common echocardiographic finding in dogs with PH secondary to respiratory diseases. Right ventricular dysfunction, dilatation, and decreased left and right ventricular stroke volume were significantly associated with the PH-related signs, indicating that comprehensive echocardiography is recommended in dogs with respiratory disease. Restricted lung disease might induce more severe PH than OALD.
MISC
125書籍等出版物
8講演・口頭発表等
47担当経験のある科目(授業)
15-
- 現在卒業論文 (日本獣医生命科学大学)
-
- 現在総合獣医学 (日本獣医生命科学大学)
-
- 現在獣医総合実習(臨床)Ⅲ (日本獣医生命科学大学)
-
- 現在獣医総合実習(臨床)Ⅱ (日本獣医生命科学大学)
-
- 現在獣医総合実習(臨床)Ⅰ (日本獣医生命科学大学)
共同研究・競争的資金等の研究課題
5-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2021年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2021年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2018年4月 - 2021年3月
-
日本学術振興会 科学研究費助成事業 若手研究(B) 2016年4月 - 2018年3月
-
日本学術振興会 科学研究費助成事業 若手研究(B) 2012年4月 - 2014年3月